NLS Pharmaceutics AG (NLSP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

NLS Pharmaceutics AG

NASDAQ: NLSP · Real-Time Price · USD
2.00
-0.12 (-5.66%)
At close: Oct 03, 2025, 3:59 PM
1.98
-0.75%
After-hours: Oct 03, 2025, 07:41 PM EDT

NLS Pharmaceutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
3.32K 11.41K 11.41K 10.05K
Gross Profit
-3.32K -11.41K -11.41K -10.05K
Operating Income
-4.38M -11.81M -15.48M -11.86M
Interest Income
n/a n/a 100.87 68.13
Pretax Income
-1.98M -12.17M -16.5M -11.95M
Net Income
-1.98M -12.17M -16.5M -11.95M
Selling & General & Admin
3.21M 5.9M 6.49M 5.93M
Research & Development
422.05K 5.91M 8.98M 5.92M
Other Expenses
743.84K n/a n/a n/a
Operating Expenses
4.38M 11.81M 15.47M 11.85M
Interest Expense
150.02K 145.15K 100.87K 68.13K
Selling & Marketing Expenses
n/a n/a 6.49M 5.93M
Cost & Expenses
4.38M 11.81M 15.48M 11.86M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
753K 38.18M 19.68M 14.75M
Shares Outstanding (Diluted)
1.54M 38.18M 19.68M 14.75M
EPS (Basic)
-2.63 -0.32 -0.84 -0.81
EPS (Diluted)
-2.63 -0.32 -0.84 -0.81
EBITDA
-3.63M -11.8M -15.47M -11.85M
EBIT
-3.64M -11.81M -15.48M -11.88M
Depreciation & Amortization
3.32K 11.41K 11.41K 10.05K